Á¦28Â÷ ´ëÇѳëÀο©¼ºÀÇÇÐȸ Ãß°èÇмú´ëȸ : 2021-12-12±³À°ÀÏÀÚ : 2021-12-12
±³À°Àå¼Ò : ¼¿ï´ëÇб³ »ï¼º¾Ï¿¬±¸¼Ò ÀÌ°ÇÈñȦ
±³À°ÁÖÁ¦ :
Á¦28Â÷ ´ëÇѳëÀο©¼ºÀÇÇÐȸ Ãß°èÇмú´ëȸÁÖÃÖ±â°ü : ´ëÇÑÆó°æÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѳëÀο©¼ºÀÇÇÐȸ
´ã´çÀÚ : ±èº¸¶÷
¿¬¶ôó : 070-2073-8911
À̸ÞÀÏ :
kbr12190409@naver.com ±³À°Á¾·ù : »êºÎÀΰú»ý¸®ÇÐ, ÀÇ·áÄ¿¹Â´ÏÄÉÀ̼Ç
Âü¼®¿¹»óÀοø : 50¸í
Èñ¸ÁÆòÁ¡ : 5Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 5 ½Ã°£ 40ºÐ
¼¼ºÎ¼ö°·á : 30,000¿ø
ºñ°í ÇöÀåµî·Ï : Àü¹®ÀÇ 30,000¿ø / Àü°øÀÇ °£È£»ç ±âŸ : 20,000¿ø »çÀüµî·Ï : Àü¹®ÀÇ 20,000¿ø / Àü°øÀÇ °£È£»ç ±âŸ : 10,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 12-12 ÀÌ°ÇÈñȦ 09:00~09:20 Menopause and geripause : What ±è¼º¿ì(¼¿ïÀÇ´ë)
±³À°½Ã°£ 12-12 ÀÌ°ÇÈñȦ 09:20~09:40 What's the "Geriatric Syndrome(³ëÀÎÁõÈıº)" ? ±è¼±¹Ì(¼¿ïÀÇ´ë)
±³À°½Ã°£ 12-12 ÀÌ°ÇÈñȦ 09:40~10:00 How to evaluate and manage dysmobility syndrome? ¹ÚÇü¹«(±×·¹À̽ºº´¿ø)
Åä·Ð 12-12 ÀÌ°ÇÈñȦ 10:00~10:10 Åä·Ð ()
ÈÞ½Ä 12-12 ÀÌ°ÇÈñȦ 10:10~10:30 ÈÞ½Ä ()
±³À°½Ã°£ 12-12 ÀÌ°ÇÈñȦ 10:30~10:50 Àú¿ë·®/ÃÊÀú¿ë·® Æó°æÈ£¸£¸ó Ä¡·áÀÇ È¿°ú¿Í ¾ÈÀü¼º À̵¿À±(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 12-12 ÀÌ°ÇÈñȦ 10:50~11:10 ¹è´¢Àå¾Ö(¾ß°£´¢, ±Þ¹Ú´¢, ¿ä½Ç±Ý)ÀÇ Áø´Ü°ú Ä¡·á ÀÌ»ç¶ó(¿ï»êÀÇ´ë)
±³À°½Ã°£ 12-12 ÀÌ°ÇÈñȦ 11:10~11:30 ³ëÀο©¼ºÀÇ Ç÷°ü¿îµ¿¼º Áõ»ó ¹ÚÁØö(°è¸íÀÇ´ë)
Åä·Ð 12-12 ÀÌ°ÇÈñȦ 11:30~11:40 Åä·Ð ()
±³À°½Ã°£ 12-12 ÀÌ°ÇÈñȦ 11:40~12:00 New treatment paradigm in the fight against osteoporosis; Denosumab & Romosozumab ÀÌÁö¿µ(°Ç±¹ÀÇ´ë)
½Ä»ç 12-12 12:00~13:00 ½Ä»ç ()
±³À°½Ã°£ 12-12 ÀÌ°ÇÈñȦ 13:00~13:20 Human inflammaging, the basis of most age-related diseases (ARD) ÀÌÀº½Ç(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 12-12 ÀÌ°ÇÈñȦ 13:20~13:40 ¸é¿ª·Â°ú Ç×»êÈ °Ë»çÀÇ Á¾·ù ¹× ÀÇÀÇ (NK cell µî) ±è¿µ»ó(Â÷ÀÇ´ë°¡Á¤ÀÇÇаú)
±³À°½Ã°£ 12-12 ÀÌ°ÇÈñȦ 13:40~14:00 ¸é¿ª ¿ä¹ýÀÇ Çã¿Í ½Ç (¶Ç´Â ¾ÏÄ¡·á¿¡ µµ¿òÀÌ µÇ´Â ¸é¿ª ¿ä¹ý) À±»óÈñ(ÀÎÁ¦ÀÇ´ë)
Åä·Ð 12-12 ÀÌ°ÇÈñȦ 14:00~14:10 Åä·Ð ()
ÈÞ½Ä 12-12 ÀÌ°ÇÈñȦ 14:10~14:30 ÈÞ½Ä ()
±³À°½Ã°£ 12-12 ÀÌ°ÇÈñȦ 14:30~14:50 Calorie restriction and dietary restriction mimetics (metformin etc..) ±èÁøÁÖ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 12-12 ÀÌ°ÇÈñȦ 14:50~15:10 Role of the gut microbiota in anti-aging intervention Á¶¹®°æ(Àü³²ÀÇ´ë)
±³À°½Ã°£ 12-12 ÀÌ°ÇÈñȦ 15:10~15:30 ³ëÀÎ °íÁöÇ÷Áõ ȯÀÚÀÇ °ü¸® ÀÌÀçÈÆ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 12-12 ÀÌ°ÇÈñȦ 15:30~15:50 ³ëÀÎ ºñ¸¸ÀÇ °ü¸® : risk of sardopenic obesity vs obesity paradox Ȳ±Ô¸®(¼¿ïÀÇ´ë)
±³À°½Ã°£ 12-12 ÀÌ°ÇÈñȦ 15:50~16:10 ³ëÀΰǰ ÁõÁøÀ» À§ÇÑ ¿µ¾çÁ¦ÀÇ ¼±Åà ÀÌÀ±°æ(Â÷ÀÇ´ë Â÷¿ò °¡Á¤ÀÇÇаú)
Åä·Ð 12-12 ÀÌ°ÇÈñȦ 16:10~16:20 Åä·Ð ()